BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...satraplatin Intercell AG $338.7 million $1.8 billion (2009) • Lack of commercial drivers Merged with Vivalis S.A....
BioCentury | Aug 10, 2015
Company News

Intercell, Novartis deal

...termination fee. In 2006, Intercell granted Novartis rights to Ixiaro. In 2013, Intercell merged with Vivalis S.A....
BioCentury | Apr 14, 2014
Clinical News

IC43: Phase II/III ongoing

...Valneva could not be reached for additional details. Valneva was formed through the merger of Vivalis S.A....
BioCentury | Mar 3, 2014
Company News

Valneva, Sanofi deal

...and Sanofi could not be reached. The deal was originally signed between Sanofi Pasteur and Vivalis S.A....
BioCentury | Nov 18, 2013
Clinical News

AERAS-456: Phase I/IIa started

...AG to the IC31 adjuvant used in the vaccine. Earlier this year, Intercell merged with Vivalis S.A....
BioCentury | Nov 4, 2013
Clinical News

IC43: Phase II/III halted

...doses of IC43 7 days apart or placebo. Valneva was formed through the merger of Vivalis S.A....
BioCentury | Nov 1, 2013
Clinical News

Valneva falls on IC43 vaccine trial update

...two outer membrane proteins of P. aeruginosa . Valneva was formed through the merger of Vivalis S.A....
BioCentury | Oct 7, 2013
Clinical News

C: Phase Ib data

...no safety concerns (see BioCentury, Nov. 14, 2011). Valneva was formed through the merger of Vivalis S.A....
BioCentury | Jul 29, 2013
Clinical News

Ixiaro regulatory update

...Pakistan, Nepal and Bhutan under a 2005 deal with Intercell AG , which merged with Vivalis S.A....
BioCentury | Jul 15, 2013
Finance

Highlights of weekly biotech stock moves

...shares at €2.65 in a rights offering. Valneva was formed through the May merger of Vivalis S.A....
Items per page:
1 - 10 of 81
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...satraplatin Intercell AG $338.7 million $1.8 billion (2009) • Lack of commercial drivers Merged with Vivalis S.A....
BioCentury | Aug 10, 2015
Company News

Intercell, Novartis deal

...termination fee. In 2006, Intercell granted Novartis rights to Ixiaro. In 2013, Intercell merged with Vivalis S.A....
BioCentury | Apr 14, 2014
Clinical News

IC43: Phase II/III ongoing

...Valneva could not be reached for additional details. Valneva was formed through the merger of Vivalis S.A....
BioCentury | Mar 3, 2014
Company News

Valneva, Sanofi deal

...and Sanofi could not be reached. The deal was originally signed between Sanofi Pasteur and Vivalis S.A....
BioCentury | Nov 18, 2013
Clinical News

AERAS-456: Phase I/IIa started

...AG to the IC31 adjuvant used in the vaccine. Earlier this year, Intercell merged with Vivalis S.A....
BioCentury | Nov 4, 2013
Clinical News

IC43: Phase II/III halted

...doses of IC43 7 days apart or placebo. Valneva was formed through the merger of Vivalis S.A....
BioCentury | Nov 1, 2013
Clinical News

Valneva falls on IC43 vaccine trial update

...two outer membrane proteins of P. aeruginosa . Valneva was formed through the merger of Vivalis S.A....
BioCentury | Oct 7, 2013
Clinical News

C: Phase Ib data

...no safety concerns (see BioCentury, Nov. 14, 2011). Valneva was formed through the merger of Vivalis S.A....
BioCentury | Jul 29, 2013
Clinical News

Ixiaro regulatory update

...Pakistan, Nepal and Bhutan under a 2005 deal with Intercell AG , which merged with Vivalis S.A....
BioCentury | Jul 15, 2013
Finance

Highlights of weekly biotech stock moves

...shares at €2.65 in a rights offering. Valneva was formed through the May merger of Vivalis S.A....
Items per page:
1 - 10 of 81